Tier 2 — strong

Is Urolithin A(UA) a pharmacologically credible neuro-nutraceutical? A critical review of mechanisms, brain exposure, and evidence gaps in Alzheimer's and Parkinson's disease

Oswal DG, Rane M
Neurochemistry International 2026 199:106224

Bibliography

PubMed
PMID 42468665
DOI
10.1016/j.neuint.2026.106224
Competing interests
The authors declared no known competing financial interests or personal relationships.

Study snapshot

DesignCritical narrative review
ModelPreclinical neurodegeneration literature plus available human Urolithin A pharmacology/clinical studies
SampleNot applicable
InterventionReview of Urolithin A mechanisms, brain exposure and translational evidence
DurationNot applicable
EndpointsPINK1/Parkin mitophagy; Neuroinflammation; Brain exposure and conjugated metabolites; Alzheimer's and Parkinson's models; Human clinical evidence gaps

What the study showed, in plain terms

This independent 2026 review asks the question marketing pages often skip: is the brain evidence pharmacologically credible in humans? It finds strong preclinical neuroprotective biology but emphasizes that circulating Urolithin A in humans is largely conjugated and no completed trial has yet demonstrated cognitive or neurodegenerative disease modification.

Key findings

Preclinical evidence supports PINK1/Parkin mitophagy and anti-neuroinflammatory effects.

Human evidence establishes peripheral safety, pharmacokinetics and mitochondrial target engagement rather than CNS efficacy.

Dedicated human cognitive/neurodegenerative outcome trials remain the key missing step.

What this study can and cannot tell us

Narrative review rather than a new clinical trial.

Preclinical models dominate the brain evidence.

Direct free Urolithin A exposure in human brain tissue remains uncertain.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology